Comparing telehealth and in-person assessments for glioma patients on oral chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase IV trial evaluates patient satisfaction between telehealth and in-person neuro-oncology assessments for glioma patients receiving oral chemotherapy. The study aims to measure satisfaction through Press-Ganey survey scores and assess the completion rates of chemotherapy, patient preferences, acute care utilization, neurological impairment, and quality of life. By utilizing telehealth, the trial seeks to address barriers that glioma patients may face in accessing high-quality care. The study will involve patients receiving temozolomide, with assessments conducted over a 28-day period following each type of visit.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Diagnosis of glioma requiring adjuvant chemotherapy. Patients with glioblastoma (GBM); astrocytoma, IDH-mutant; oligodendroglioma IDH-mutant, 1p/19q codeleted are eligible
* Patients eligible to receive temozolomide as standard of care adjuvant therapy
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, AND Karnofsky performance status (KPS) of ≥ 60
* Expected survival ≥ 6 months in the opinion of treatment team
* Willing and able to adhere with the protocol for the duration of the study including undergoing treatment, and attending scheduled visits, and examinations
* Participants who do not have devices that will permit telehealth visits will be provided such tablet devices to facilitate appointments for the duration of the study
* Participants who do not have financial resources to travel for in-person visits will be provided assistance for cost of travel
* Ability to complete patient experience surveys by the participant with or without assistance from their caregiver

Exclusion Criteria:

* Uncontrolled and/or intercurrent illness or other condition which limits safety of or compliance with study proceedings
* Pregnant or nursing, imprisoned, or lacking capacity for understanding
* Unable to swallow tablets or at risk for impaired absorption of oral medication
* Known hypersensitivity or allergy to temozolomide

Where it's running

• Mayo Clinic in Rochester
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Ugur T. Sener, MD — Mayo Clinic
• Study coordinator: Clinical Trials Referral Office
• Email: mayocliniccancerstudies@mayo.edu
• Phone: 855-776-0015

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• YN003 injection in glioma patients

  This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.

  Recruiting at 2 sites Phase 1 Beijing Inno Medicine Co., Ltd. · Los Angeles, California and 4 other locations · NCT07929909

• Brain connectome project in adults with brain glioma undergoing surgery

  This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.

  Recruiting Northwell Health · New York, New York · NCT07927595

• Sitagliptin plus bevacizumab for recurrent grade 4 glioma

  This study tests whether adding sitagliptin to bevacizumab can help people whose recurrent glioblastoma or other grade 4 gliomas respond to treatment and to find a safe dose when used with bevacizumab.

  Recruiting Phase 1 University of Iowa · Iowa City, Iowa · NCT07541781

• Phase 1 safety and dose-finding of GLIX1 for adults with recurrent or progressive high-grade glioma

  This trial will test whether taking oral GLIX1 daily is safe, tolerable, and shows early anti-tumor activity in adults with recurrent or progressive high-grade glioma.

  Recruiting at 4 sites Phase 1 Tetragon Biosciences Ltd · Palo Alto, California and 3 other locations · NCT07464925

• Skin closure after brain tumor surgery: running absorbable versus interrupted non-absorbable sutures

  This will test whether absorbable running intradermal sutures or non-absorbable interrupted transdermal sutures produce better wound healing after craniotomy in adults with supratentorial brain tumors.

  Recruiting Medical University of Warsaw · Warsaw, Masovian Voivodeship · NCT07413796

• Cerebrospinal fluid leak after brain tumor surgery

  This project will look at adults having planned supratentorial craniotomy for intracranial tumors to see how often cerebrospinal fluid leaks occur and what complications they cause.

  Recruiting Medical University of Warsaw · Warsaw · NCT07411690

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.